BioSpring Biomedical Co. Ltd. entered into a binding memorandum of understanding to acquire Mercurius Capital Investment Limited (Catalist:5RF) in a reverse merger transaction on July 1, 2024. The MOU shall remain in effect for a period of one year from the date of signing.

Subject to execution of the definitive agreements, Mercurius Capital will convene an extraordinary general meeting to seek the approval of the shareholders for the Proposed Transaction in due course.